<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='181'><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1036908">SynDevRx Inc</Company><Country id="US">US</Country><Drug id="73940">SDX-7320</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-06 00:00:00</LatestChange><ParentCompany id="1036908">SynDevRx Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-01-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="US">US</Country><Drug id="90651">ZGN-839</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="3288">Non alcoholic fatty liver disease</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-04-18 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-04-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="US">US</Country><Drug id="61782">beloranib hemioxalate (obesity), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="238">Obesity</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-31 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-03-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="AU">Australia</Country><Drug id="61782">beloranib hemioxalate (obesity), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="238">Obesity</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-31 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-03-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30764">IDRTech Inc</Company><Country id="KR">South Korea</Country><Drug id="45864">IDR-805</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-04 00:00:00</LatestChange><ParentCompany id="1031550">Equis &amp; Zaroo Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-07-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1031550">Equis &amp; Zaroo Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="45864">IDR-805</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-04 00:00:00</LatestChange><ParentCompany id="1031550">Equis &amp; Zaroo Co Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-12-04 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="21816">Leucyl cystinyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21104">St Vincents Hospital (Melbourne) Ltd</Company><Country id="AU">Australia</Country><Drug id="75789">IRAP inhibitors (cardiovascular diseases/CNS diseases), University of Florey Institute/Monash University/University of Melbourne/ St Vincent's Institute of Medical Research/ Bio-Link</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="60">Central nervous system disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="21104">St Vincents Hospital (Melbourne) Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-05-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="9287">Methionine aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24818">Novartis Pharmaceuticals Corp</Company><Country id="US">US</Country><Drug id="37189">MetAp inhibitor, Novartis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-09-09 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-09-09 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20610">Loyola University of Chicago</Company><Country id="US">US</Country><Drug id="16230">apstatin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1005">Unidentified indication</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-02-17 00:00:00</LatestChange><ParentCompany id="20610">Loyola University of Chicago</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-02-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="1005">Unidentified indication</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20686">Tokyo University</Company><Country id="JP">Japan</Country><Drug id="25733">aminopeptidase inhibitors, Tokyo University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-28 00:00:00</LatestChange><ParentCompany id="20686">Tokyo University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-04-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="936">Kaposis sarcoma</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="427">Uterine cervix tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="1521">Gynecology and obstetrics</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15931">TAP Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="249">Pancreas tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="13601">Abbott Laboratories</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1999-01-01 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15262">Vernalis plc</Company><Country id="GB">UK</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="15262">Vernalis plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2007-03-26 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29495">Chroma Therapeutics Ltd</Company><Country id="GB">UK</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1272">Myelodysplastic syndrome</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="29495">Chroma Therapeutics Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-10-27 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15337">CTI BioPharma Corp</Company><Country id="US">US</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1828">Multiple myeloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="15337">CTI BioPharma Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18535">Nippon Kayaku Co Ltd</Company><Country id="JP">Japan</Country><Drug id="9560">ubenimex</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="54">Carcinoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1996-12-31 00:00:00</LatestChange><ParentCompany id="18535">Nippon Kayaku Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1995-05-20 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="38552">Glutamyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1021272">Quantum Genomics Corp</Company><Country id="US">US</Country><Drug id="89503">QGC-011</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="178">Hypertension</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-02 00:00:00</LatestChange><ParentCompany id="1021272">Quantum Genomics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-01-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15410">Chong Kun Dang Pharmaceutical Corp</Company><Country id="US">US</Country><Drug id="75504">beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="238">Obesity</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-15 00:00:00</LatestChange><ParentCompany id="15410">Chong Kun Dang Pharmaceutical Corp</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2008-11-06 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="X5">Europe</Country><Drug id="75504">beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="2890">Prader-Willi syndrome</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-15 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-05-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="US">US</Country><Drug id="75504">beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="2890">Prader-Willi syndrome</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-15 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2013-06-25 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="US">US</Country><Drug id="90651">ZGN-839</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="2637">Non-alcoholic steatohepatitis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-04-18 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-03-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="US">US</Country><Drug id="90651">ZGN-839</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="238">Obesity</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-04-18 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-04-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1036908">SynDevRx Inc</Company><Country id="US">US</Country><Drug id="59094">SDX-7175</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-08 00:00:00</LatestChange><ParentCompany id="1036908">SynDevRx Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-01-08 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1067932">University of Maryland Office of Technology Commercialization</Company><Country id="US">US</Country><Drug id="75995">fumagillin (giardiasis), University of Maryland</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="133">Giardia lamblia infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-02-10 00:00:00</LatestChange><ParentCompany id="20611">University of Maryland</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="21816">Leucyl cystinyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21104">St Vincents Hospital (Melbourne) Ltd</Company><Country id="AU">Australia</Country><Drug id="75789">IRAP inhibitors (cardiovascular diseases/CNS diseases), University of Florey Institute/Monash University/University of Melbourne/ St Vincent's Institute of Medical Research/ Bio-Link</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="60">Central nervous system disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="21104">St Vincents Hospital (Melbourne) Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-09-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="21816">Leucyl cystinyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21077">Howard Florey Institute</Company><Country id="AU">Australia</Country><Drug id="75789">IRAP inhibitors (cardiovascular diseases/CNS diseases), University of Florey Institute/Monash University/University of Melbourne/ St Vincent's Institute of Medical Research/ Bio-Link</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="57">Cardiovascular disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="21077">Howard Florey Institute</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-05-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="21816">Leucyl cystinyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20620">University of Melbourne</Company><Country id="AU">Australia</Country><Drug id="75789">IRAP inhibitors (cardiovascular diseases/CNS diseases), University of Florey Institute/Monash University/University of Melbourne/ St Vincent's Institute of Medical Research/ Bio-Link</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="60">Central nervous system disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="20620">University of Melbourne</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-07-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="755">Lung tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1996-04-01 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17229">INSERM</Company><Country id="FR">France</Country><Drug id="26410">EC-33</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="178">Hypertension</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-05-27 00:00:00</LatestChange><ParentCompany id="17229">INSERM</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-05-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29495">Chroma Therapeutics Ltd</Company><Country id="US">US</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1828">Multiple myeloma</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="29495">Chroma Therapeutics Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-10-27 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29495">Chroma Therapeutics Ltd</Company><Country id="GB">UK</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1272">Myelodysplastic syndrome</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="29495">Chroma Therapeutics Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2007-03-26 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15337">CTI BioPharma Corp</Company><Country id="US">US</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="15337">CTI BioPharma Corp</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-04-12 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18535">Nippon Kayaku Co Ltd</Company><Country id="JP">Japan</Country><Drug id="9560">ubenimex</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1996-12-31 00:00:00</LatestChange><ParentCompany id="18535">Nippon Kayaku Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1995-05-20 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26494">Sanofi-Synthelabo</Company><Country id="XW">Western Europe</Country><Drug id="25971">oral fumagillin (microsporidiosis), sanofi-aventis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="448">Microsporidial infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-05-14 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1999-09-01 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24240">Praecis Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="37752">PPI-2458</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="319">Non-Hodgkin lymphoma</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-02-16 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-04-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15262">Vernalis plc</Company><Country id="GB">UK</Country><Drug id="29333">BB-76163</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="188">Inflammatory disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-07-26 00:00:00</LatestChange><ParentCompany id="15262">Vernalis plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-06-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="38552">Glutamyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17229">INSERM</Company><Country id="FR">France</Country><Drug id="57583">QGC-001</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="178">Hypertension</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-04-13 00:00:00</LatestChange><ParentCompany id="17229">INSERM</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-08-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="38552">Glutamyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1038323">APAvadis Biotechnologies srl</Company><Country id="IT">Italy</Country><Drug id="78982">aminopeptidase A inhibitor (cancer/endometriosis), APAvadis</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-28 00:00:00</LatestChange><ParentCompany id="1038323">APAvadis Biotechnologies srl</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-06-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="US">US</Country><Drug id="65967">fumagillin (obesity/type 2 diabetes), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-10-31 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-10-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="85166">fumagillin analogs (angiogenesis dependant diseases), Johns Hopkins University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="422">Angiogenesis disorder</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-20 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-09-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18101">Merck KGaA</Company><Country id="DE">Germany</Country><Drug id="92794">MetAP-2 inhibitors (cancer), Merck KGaA</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-09-08 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-09-08 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="US">US</Country><Drug id="90652">second generation beloranib (obesity), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="238">Obesity</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-03-31 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-03-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="21816">Leucyl cystinyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21077">Howard Florey Institute</Company><Country id="AU">Australia</Country><Drug id="75789">IRAP inhibitors (cardiovascular diseases/CNS diseases), University of Florey Institute/Monash University/University of Melbourne/ St Vincent's Institute of Medical Research/ Bio-Link</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="60">Central nervous system disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="21077">Howard Florey Institute</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-05-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="21816">Leucyl cystinyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20629">Monash University</Company><Country id="AU">Australia</Country><Drug id="75789">IRAP inhibitors (cardiovascular diseases/CNS diseases), University of Florey Institute/Monash University/University of Melbourne/ St Vincent's Institute of Medical Research/ Bio-Link</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="57">Cardiovascular disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="20629">Monash University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-05-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="9287">Methionine aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24818">Novartis Pharmaceuticals Corp</Company><Country id="US">US</Country><Drug id="37189">MetAp inhibitor, Novartis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-09-09 00:00:00</LatestChange><ParentCompany id="23137">Novartis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-12-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="276">Prostate tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="1785">Andrology</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="194">Sarcoma</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15931">TAP Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="49">Breast tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="13601">Abbott Laboratories</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2002-07-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15931">TAP Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="249">Pancreas tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="13601">Abbott Laboratories</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2002-07-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21948">GlaxoSmithKline Inc</Company><Country id="US">US</Country><Drug id="39195">MetAP2 inhibitors, GSK</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2006-10-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-04-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29495">Chroma Therapeutics Ltd</Company><Country id="GB">UK</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="29495">Chroma Therapeutics Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-04-12 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15337">CTI BioPharma Corp</Company><Country id="X1">Americas</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="15337">CTI BioPharma Corp</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-04-12 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17229">INSERM</Company><Country id="FR">France</Country><Drug id="8587">enkephalinase inhibitors (major depressive disorder/pain), INSERM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="93">Depression</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-23 00:00:00</LatestChange><ParentCompany id="17229">INSERM</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-12-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17229">INSERM</Company><Country id="FR">France</Country><Drug id="8587">enkephalinase inhibitors (major depressive disorder/pain), INSERM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="20">Pain</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-23 00:00:00</LatestChange><ParentCompany id="17229">INSERM</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-12-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17229">INSERM</Company><Country id="FR">France</Country><Drug id="28553">dual enkephalin-degrading enzyme inhibitors, Sanofi-Synthelabo/INSERM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="20">Pain</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-01-15 00:00:00</LatestChange><ParentCompany id="17229">INSERM</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-09-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29481">Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Company><Country id="US">US</Country><Drug id="56336">LTA4H inhibitor (inflammation), Johnson &amp; Johnson</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="188">Inflammatory disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-03-28 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-05-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15262">Vernalis plc</Company><Country id="GB">UK</Country><Drug id="44121">methionine aminopeptidase inhibitors (bacterial infection), Genesoft</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="40">Bacterial infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-04-13 00:00:00</LatestChange><ParentCompany id="15262">Vernalis plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-03-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24240">Praecis Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="37752">PPI-2458</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="725">Solid tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-02-16 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-02-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="38552">Glutamyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17229">INSERM</Company><Country id="US">US</Country><Drug id="89503">QGC-011</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="178">Hypertension</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-02 00:00:00</LatestChange><ParentCompany id="17229">INSERM</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-01-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="38552">Glutamyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17229">INSERM</Company><Country id="US">US</Country><Drug id="89507">QGC-101</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="55">Cardiac failure</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-02 00:00:00</LatestChange><ParentCompany id="17229">INSERM</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-01-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><Drug id="34819">MetAP2 inhibitors (anticancer), Abbott</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-07-07 00:00:00</LatestChange><ParentCompany id="13601">Abbott Laboratories</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-06-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1002523">Mersana Therapeutics Inc</Company><Country id="US">US</Country><Drug id="59189">XMT-1107</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="725">Solid tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-04-13 00:00:00</LatestChange><ParentCompany id="1002523">Mersana Therapeutics Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2010-04-12 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="US">US</Country><Drug id="65967">fumagillin (obesity/type 2 diabetes), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="238">Obesity</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-10-31 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-10-31 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="US">US</Country><Drug id="65967">fumagillin (obesity/type 2 diabetes), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="238">Obesity</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-10-31 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-09-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="AU">Australia</Country><Drug id="75504">beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="238">Obesity</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-15 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-08-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28026">Astex Therapeutics Ltd</Company><Country id="GB">UK</Country><Drug id="62144">MetAP2 inhibitors (cancer), Astex</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-02 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2011-07-20 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="US">US</Country><Drug id="61782">beloranib hemioxalate (obesity), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="238">Obesity</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-31 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-11-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="21816">Leucyl cystinyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20629">Monash University</Company><Country id="AU">Australia</Country><Drug id="75789">IRAP inhibitors (cardiovascular diseases/CNS diseases), University of Florey Institute/Monash University/University of Melbourne/ St Vincent's Institute of Medical Research/ Bio-Link</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="60">Central nervous system disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="20629">Monash University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-05-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="9287">Methionine aminopeptidase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15996">Morphochem AG</Company><Country id="DE">Germany</Country><Drug id="51166">methionine aminopeptidase inhibitors, Morphochem</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="40">Bacterial infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-12-03 00:00:00</LatestChange><ParentCompany id="1008599">Biovertis AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-12-03 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="9287">Methionine aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1083716">Johns Hopkins University Office of Technology Transfer</Company><Country id="US">US</Country><Drug id="89387">Methionine aminopeptidase inhibitors (Mycobacterium tuberculosis), Johns Hopkins University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-19 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="755">Lung tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15931">TAP Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="49">Breast tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="13601">Abbott Laboratories</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1999-01-01 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15931">TAP Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1108">Glioma</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="13601">Abbott Laboratories</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1999-01-01 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21948">GlaxoSmithKline Inc</Company><Country id="US">US</Country><Drug id="39195">MetAP2 inhibitors, GSK</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2006-10-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2006-10-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29495">Chroma Therapeutics Ltd</Company><Country id="GB">UK</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="725">Solid tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="29495">Chroma Therapeutics Ltd</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2004-11-16 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29495">Chroma Therapeutics Ltd</Company><Country id="GB">UK</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1828">Multiple myeloma</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="29495">Chroma Therapeutics Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29495">Chroma Therapeutics Ltd</Company><Country id="US">US</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1262">Non-small-cell lung cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="29495">Chroma Therapeutics Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-03-14 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29495">Chroma Therapeutics Ltd</Company><Country id="US">US</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1262">Non-small-cell lung cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="29495">Chroma Therapeutics Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2007-08-29 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15337">CTI BioPharma Corp</Company><Country id="US">US</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1272">Myelodysplastic syndrome</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="15337">CTI BioPharma Corp</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-03-14 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20547">University of California</Company><Country id="US">US</Country><Drug id="70705">dipeptidyl aminopeptidase I inhibitors (malaria), Stanford University/ University of California</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="267">Plasmodium falciparum infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-01 00:00:00</LatestChange><ParentCompany id="20547">University of California</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-10-01 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1009547">Sanofi</Company><Country id="FR">France</Country><Drug id="25971">oral fumagillin (microsporidiosis), sanofi-aventis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="448">Microsporidial infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-05-14 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2004-12-13 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><Drug id="28553">dual enkephalin-degrading enzyme inhibitors, Sanofi-Synthelabo/INSERM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="20">Pain</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-01-15 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2004-01-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24240">Praecis Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="37752">PPI-2458</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-02-16 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-04-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1070628">Zhejiang Apeloa Kangyu Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="81801">ubenimex (oral capsule, cancer), Apeloa</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1050881">Hengdian Group Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1070628">Zhejiang Apeloa Kangyu Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="81801">ubenimex (oral capsule, cancer), Apeloa</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1050881">Hengdian Group Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19862">Merck Serono SA</Company><Country id="GB">UK</Country><Drug id="29333">BB-76163</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="188">Inflammatory disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-07-26 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-10-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="38552">Glutamyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1021272">Quantum Genomics Corp</Company><Country id="FR">France</Country><Drug id="57583">QGC-001</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="178">Hypertension</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-04-13 00:00:00</LatestChange><ParentCompany id="1021272">Quantum Genomics Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-04-13 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="38552">Glutamyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1021272">Quantum Genomics Corp</Company><Country id="US">US</Country><Drug id="78079">QGC-006</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1559">Congestive heart failure</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-21 00:00:00</LatestChange><ParentCompany id="1021272">Quantum Genomics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-06-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="38552">Glutamyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1038323">APAvadis Biotechnologies srl</Company><Country id="IT">Italy</Country><Drug id="78982">aminopeptidase A inhibitor (cancer/endometriosis), APAvadis</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="113">Endometriosis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-28 00:00:00</LatestChange><ParentCompany id="1038323">APAvadis Biotechnologies srl</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-06-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="1521">Gynecology and obstetrics</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="IL">Israel</Country><Drug id="59189">XMT-1107</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-04-13 00:00:00</LatestChange><ParentCompany id="20348">Teva Pharmaceutical Industries Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-04-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="US">US</Country><Drug id="65967">fumagillin (obesity/type 2 diabetes), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-10-31 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-06-26 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1036908">SynDevRx Inc</Company><Country id="US">US</Country><Drug id="73940">SDX-7320</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-06 00:00:00</LatestChange><ParentCompany id="1036908">SynDevRx Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="AU">Australia</Country><Drug id="75504">beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-15 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2014-12-15 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1083716">Johns Hopkins University Office of Technology Transfer</Company><Country id="US">US</Country><Drug id="85166">fumagillin analogs (angiogenesis dependant diseases), Johns Hopkins University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="422">Angiogenesis disorder</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-20 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-05-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20611">University of Maryland</Company><Country id="US">US</Country><Drug id="75995">fumagillin (giardiasis), University of Maryland</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="133">Giardia lamblia infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-02-10 00:00:00</LatestChange><ParentCompany id="20611">University of Maryland</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-02-10 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15410">Chong Kun Dang Pharmaceutical Corp</Company><Country id="KR">South Korea</Country><Drug id="61782">beloranib hemioxalate (obesity), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="725">Solid tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-31 00:00:00</LatestChange><ParentCompany id="15410">Chong Kun Dang Pharmaceutical Corp</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2008-11-06 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24839">Harvard Medical School</Company><Country id="US">US</Country><Drug id="59094">SDX-7175</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-01-08 00:00:00</LatestChange><ParentCompany id="24839">Harvard Medical School</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-01-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24839">Harvard Medical School</Company><Country id="US">US</Country><Drug id="59094">SDX-7175</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-01-08 00:00:00</LatestChange><ParentCompany id="24839">Harvard Medical School</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2008-01-08 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28026">Astex Therapeutics Ltd</Company><Country id="GB">UK</Country><Drug id="62144">MetAP2 inhibitors (cancer), Astex</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-02 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-12-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="AU">Australia</Country><Drug id="61782">beloranib hemioxalate (obesity), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="238">Obesity</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-31 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-12-31 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="AU">Australia</Country><Drug id="61782">beloranib hemioxalate (obesity), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="238">Obesity</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-31 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2009-12-07 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21885">Astex Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="62144">MetAP2 inhibitors (cancer), Astex</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-02 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-07-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="21816">Leucyl cystinyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20629">Monash University</Company><Country id="AU">Australia</Country><Drug id="75789">IRAP inhibitors (cardiovascular diseases/CNS diseases), University of Florey Institute/Monash University/University of Melbourne/ St Vincent's Institute of Medical Research/ Bio-Link</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="57">Cardiovascular disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="20629">Monash University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-09-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="21816">Leucyl cystinyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20620">University of Melbourne</Company><Country id="AU">Australia</Country><Drug id="75789">IRAP inhibitors (cardiovascular diseases/CNS diseases), University of Florey Institute/Monash University/University of Melbourne/ St Vincent's Institute of Medical Research/ Bio-Link</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="60">Central nervous system disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="20620">University of Melbourne</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-05-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="9287">Methionine aminopeptidase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15996">Morphochem AG</Company><Country id="DE">Germany</Country><Drug id="51166">methionine aminopeptidase inhibitors, Morphochem</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="40">Bacterial infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-12-03 00:00:00</LatestChange><ParentCompany id="1008599">Biovertis AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-06-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="49">Breast tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="427">Uterine cervix tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1996-04-01 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="1521">Gynecology and obstetrics</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29495">Chroma Therapeutics Ltd</Company><Country id="GB">UK</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="725">Solid tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="29495">Chroma Therapeutics Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-01-01 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15337">CTI BioPharma Corp</Company><Country id="US">US</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="15337">CTI BioPharma Corp</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-03-14 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17229">INSERM</Company><Country id="FR">France</Country><Drug id="8587">enkephalinase inhibitors (major depressive disorder/pain), INSERM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="20">Pain</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-23 00:00:00</LatestChange><ParentCompany id="17229">INSERM</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1992-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1009547">Sanofi</Company><Country id="XW">Western Europe</Country><Drug id="25971">oral fumagillin (microsporidiosis), sanofi-aventis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="448">Microsporidial infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-05-14 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2004-08-20 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1067538">Janssen Research &amp; Development LLC</Company><Country id="US">US</Country><Drug id="56336">LTA4H inhibitor (inflammation), Johnson &amp; Johnson</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="188">Inflammatory disease</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-03-28 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-03-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25145">Korea Research Institute of Bioscience and Biotechnology</Company><Country id="KR">South Korea</Country><Drug id="16197">MR-387B</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-07-27 00:00:00</LatestChange><ParentCompany id="25145">Korea Research Institute of Bioscience and Biotechnology</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-10-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15262">Vernalis plc</Company><Country id="GB">UK</Country><Drug id="44121">methionine aminopeptidase inhibitors (bacterial infection), Genesoft</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="40">Bacterial infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-04-13 00:00:00</LatestChange><ParentCompany id="15262">Vernalis plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2003-10-01 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24240">Praecis Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="37752">PPI-2458</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="725">Solid tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-02-16 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19862">Merck Serono SA</Company><Country id="GB">UK</Country><Drug id="29333">BB-76163</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="188">Inflammatory disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-07-26 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2001-07-26 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="US">US</Country><Drug id="90651">ZGN-839</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-04-18 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-03-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="21816">Leucyl cystinyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20629">Monash University</Company><Country id="AU">Australia</Country><Drug id="75789">IRAP inhibitors (cardiovascular diseases/CNS diseases), University of Florey Institute/Monash University/University of Melbourne/ St Vincent's Institute of Medical Research/ Bio-Link</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="60">Central nervous system disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="20629">Monash University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-09-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17265">Ishihara Sangyo Kaisha Ltd</Company><Country id="JP">Japan</Country><Drug id="25733">aminopeptidase inhibitors, Tokyo University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-28 00:00:00</LatestChange><ParentCompany id="17265">Ishihara Sangyo Kaisha Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-10-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="999">Renal tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="999">Renal tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1999-05-01 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15931">TAP Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="936">Kaposis sarcoma</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="13601">Abbott Laboratories</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2002-07-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15337">CTI BioPharma Corp</Company><Country id="GB">UK</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="15337">CTI BioPharma Corp</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2014-10-27 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20679">Stanford University</Company><Country id="US">US</Country><Drug id="70705">dipeptidyl aminopeptidase I inhibitors (malaria), Stanford University/ University of California</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="267">Plasmodium falciparum infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-01 00:00:00</LatestChange><ParentCompany id="20679">Stanford University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1009547">Sanofi</Company><Country id="FR">France</Country><Drug id="25971">oral fumagillin (microsporidiosis), sanofi-aventis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="448">Microsporidial infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-05-14 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="L">Launched</Status><StatusDate>2007-05-14 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25145">Korea Research Institute of Bioscience and Biotechnology</Company><Country id="KR">South Korea</Country><Drug id="16197">MR-387B</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-07-27 00:00:00</LatestChange><ParentCompany id="25145">Korea Research Institute of Bioscience and Biotechnology</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-07-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24240">Praecis Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="37752">PPI-2458</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="291">Rheumatoid arthritis</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-02-16 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-01-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1064396">BroadSources Inc</Company><Country id="US">US</Country><Drug id="73162">MetAP2/SIRT1 dual inhibitors (cancer), BroadSources</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-08-30 00:00:00</LatestChange><ParentCompany id="1064396">BroadSources Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="US">US</Country><Drug id="75504">beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="2890">Prader-Willi syndrome</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-15 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2014-09-30 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="US">US</Country><Drug id="75504">beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="2890">Prader-Willi syndrome</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-15 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-01-15 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="US">US</Country><Drug id="75504">beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="238">Obesity</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-15 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-11-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="AU">Australia</Country><Drug id="75504">beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="238">Obesity</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-15 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-01-09 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="21816">Leucyl cystinyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21077">Howard Florey Institute</Company><Country id="AU">Australia</Country><Drug id="75789">IRAP inhibitors (cardiovascular diseases/CNS diseases), University of Florey Institute/Monash University/University of Melbourne/ St Vincent's Institute of Medical Research/ Bio-Link</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="60">Central nervous system disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="21077">Howard Florey Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-07-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="21816">Leucyl cystinyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20620">University of Melbourne</Company><Country id="AU">Australia</Country><Drug id="75789">IRAP inhibitors (cardiovascular diseases/CNS diseases), University of Florey Institute/Monash University/University of Melbourne/ St Vincent's Institute of Medical Research/ Bio-Link</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="57">Cardiovascular disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="20620">University of Melbourne</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-07-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="9287">Methionine aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="89387">Methionine aminopeptidase inhibitors (Mycobacterium tuberculosis), Johns Hopkins University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-12-19 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-01-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20610">Loyola University of Chicago</Company><Country id="US">US</Country><Drug id="16230">apstatin</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1005">Unidentified indication</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-02-17 00:00:00</LatestChange><ParentCompany id="20610">Loyola University of Chicago</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-10-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="1005">Unidentified indication</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15931">TAP Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1108">Glioma</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="13601">Abbott Laboratories</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2002-07-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29495">Chroma Therapeutics Ltd</Company><Country id="GB">UK</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="29495">Chroma Therapeutics Ltd</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2007-03-26 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15337">CTI BioPharma Corp</Company><Country id="GB">UK</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1272">Myelodysplastic syndrome</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="15337">CTI BioPharma Corp</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2014-10-27 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20679">Stanford University</Company><Country id="US">US</Country><Drug id="70705">dipeptidyl aminopeptidase I inhibitors (malaria), Stanford University/ University of California</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="267">Plasmodium falciparum infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-01 00:00:00</LatestChange><ParentCompany id="20679">Stanford University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-10-01 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17229">INSERM</Company><Country id="FR">France</Country><Drug id="8587">enkephalinase inhibitors (major depressive disorder/pain), INSERM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="93">Depression</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-12-23 00:00:00</LatestChange><ParentCompany id="17229">INSERM</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-07-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18535">Nippon Kayaku Co Ltd</Company><Country id="JP">Japan</Country><Drug id="9560">ubenimex</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1996-12-31 00:00:00</LatestChange><ParentCompany id="18535">Nippon Kayaku Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1996-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><Drug id="28553">dual enkephalin-degrading enzyme inhibitors, Sanofi-Synthelabo/INSERM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="20">Pain</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-01-15 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-09-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26495">Sanofi (pre-1999)</Company><Country id="XW">Western Europe</Country><Drug id="25971">oral fumagillin (microsporidiosis), sanofi-aventis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="448">Microsporidial infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-05-14 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>1996-11-01 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17229">INSERM</Company><Country id="FR">France</Country><Drug id="28553">dual enkephalin-degrading enzyme inhibitors, Sanofi-Synthelabo/INSERM</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="20">Pain</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-01-15 00:00:00</LatestChange><ParentCompany id="17229">INSERM</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2004-01-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28023">Genesoft Inc</Company><Country id="GB">UK</Country><Drug id="44121">methionine aminopeptidase inhibitors (bacterial infection), Genesoft</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="40">Bacterial infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-04-13 00:00:00</LatestChange><ParentCompany id="15523">Oscient Pharmaceuticals Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-10-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28023">Genesoft Inc</Company><Country id="GB">UK</Country><Drug id="44121">methionine aminopeptidase inhibitors (bacterial infection), Genesoft</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="40">Bacterial infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2004-04-13 00:00:00</LatestChange><ParentCompany id="15523">Oscient Pharmaceuticals Corp</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2004-04-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24240">Praecis Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="37752">PPI-2458</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="319">Non-Hodgkin lymphoma</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-02-16 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2003-11-19 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24240">Praecis Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="37752">PPI-2458</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-02-16 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-02-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="38552">Glutamyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1021272">Quantum Genomics Corp</Company><Country id="FR">France</Country><Drug id="57583">QGC-001</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="178">Hypertension</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-04-13 00:00:00</LatestChange><ParentCompany id="1021272">Quantum Genomics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-06-28 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="38552">Glutamyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1021272">Quantum Genomics Corp</Company><Country id="US">US</Country><Drug id="78079">QGC-006</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="178">Hypertension</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-21 00:00:00</LatestChange><ParentCompany id="1021272">Quantum Genomics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-06-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="38552">Glutamyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1021272">Quantum Genomics Corp</Company><Country id="US">US</Country><Drug id="89507">QGC-101</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="55">Cardiac failure</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-02 00:00:00</LatestChange><ParentCompany id="1021272">Quantum Genomics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-01-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="US">US</Country><Drug id="75504">beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="760">Brain tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-12-15 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2014-03-31 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1064396">BroadSources Inc</Company><Country id="US">US</Country><Drug id="73162">MetAP2/SIRT1 dual inhibitors (cancer), BroadSources</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-08-30 00:00:00</LatestChange><ParentCompany id="1064396">BroadSources Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-08-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><Drug id="34819">MetAP2 inhibitors (anticancer), Abbott</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-07-07 00:00:00</LatestChange><ParentCompany id="13601">Abbott Laboratories</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-07-07 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1002523">Mersana Therapeutics Inc</Company><Country id="US">US</Country><Drug id="59189">XMT-1107</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2010-04-13 00:00:00</LatestChange><ParentCompany id="1002523">Mersana Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-01-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1043431">Zafgen Inc</Company><Country id="US">US</Country><Drug id="61782">beloranib hemioxalate (obesity), Zafgen</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="238">Obesity</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-03-31 00:00:00</LatestChange><ParentCompany id="1043431">Zafgen Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-03-03 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21885">Astex Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="62144">MetAP2 inhibitors (cancer), Astex</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-02 00:00:00</LatestChange><ParentCompany id="1040632">Otsuka Holdings Co Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-10-02 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23844">Deutsches Krebsforschungszentrum</Company><Country id="DE">Germany</Country><Drug id="90072">metAPII inhibitors (cancer), DKFZ</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-31 00:00:00</LatestChange><ParentCompany id="23844">Deutsches Krebsforschungszentrum</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-01-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12641">Methionine aminopeptidase-2 inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1031550">Equis &amp; Zaroo Co Ltd</Company><Country id="KR">South Korea</Country><Drug id="45864">IDR-805</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-12-04 00:00:00</LatestChange><ParentCompany id="1031550">Equis &amp; Zaroo Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="21816">Leucyl cystinyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21077">Howard Florey Institute</Company><Country id="AU">Australia</Country><Drug id="75789">IRAP inhibitors (cardiovascular diseases/CNS diseases), University of Florey Institute/Monash University/University of Melbourne/ St Vincent's Institute of Medical Research/ Bio-Link</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="57">Cardiovascular disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="21077">Howard Florey Institute</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-07-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="21816">Leucyl cystinyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20620">University of Melbourne</Company><Country id="AU">Australia</Country><Drug id="75789">IRAP inhibitors (cardiovascular diseases/CNS diseases), University of Florey Institute/Monash University/University of Melbourne/ St Vincent's Institute of Medical Research/ Bio-Link</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="57">Cardiovascular disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-05-28 00:00:00</LatestChange><ParentCompany id="20620">University of Melbourne</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-05-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17229">INSERM</Company><Country id="FR">France</Country><Drug id="26410">EC-33</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="178">Hypertension</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-05-27 00:00:00</LatestChange><ParentCompany id="17229">INSERM</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-12-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20686">Tokyo University</Company><Country id="JP">Japan</Country><Drug id="25733">aminopeptidase inhibitors, Tokyo University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-28 00:00:00</LatestChange><ParentCompany id="20686">Tokyo University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-10-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="760">Brain tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="20300">Takeda Pharmaceutical Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15931">TAP Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="2441">TNP-470</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2002-07-26 00:00:00</LatestChange><ParentCompany id="13601">Abbott Laboratories</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2002-07-26 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29495">Chroma Therapeutics Ltd</Company><Country id="GB">UK</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="29495">Chroma Therapeutics Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-05-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29495">Chroma Therapeutics Ltd</Company><Country id="GB">UK</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="29495">Chroma Therapeutics Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2014-10-27 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15337">CTI BioPharma Corp</Company><Country id="X1">Americas</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1828">Multiple myeloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="15337">CTI BioPharma Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-03-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15337">CTI BioPharma Corp</Company><Country id="GB">UK</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1828">Multiple myeloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="15337">CTI BioPharma Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15337">CTI BioPharma Corp</Company><Country id="X1">Americas</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="15337">CTI BioPharma Corp</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-03-14 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15337">CTI BioPharma Corp</Company><Country id="X1">Americas</Country><Drug id="50006">tosedostat</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1272">Myelodysplastic syndrome</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-27 00:00:00</LatestChange><ParentCompany id="15337">CTI BioPharma Corp</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-03-14 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1009547">Sanofi</Company><Country id="FR">France</Country><Drug id="25971">oral fumagillin (microsporidiosis), sanofi-aventis</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="448">Microsporidial infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-05-14 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-02-24 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20547">University of California</Company><Country id="US">US</Country><Drug id="70705">dipeptidyl aminopeptidase I inhibitors (malaria), Stanford University/ University of California</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="267">Plasmodium falciparum infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-10-01 00:00:00</LatestChange><ParentCompany id="20547">University of California</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24240">Praecis Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="37752">PPI-2458</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="291">Rheumatoid arthritis</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-02-16 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-02-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24240">Praecis Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="37752">PPI-2458</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="319">Non-Hodgkin lymphoma</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2007-02-16 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2007-02-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="52">Aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15262">Vernalis plc</Company><Country id="GB">UK</Country><Drug id="29333">BB-76163</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="188">Inflammatory disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-07-26 00:00:00</LatestChange><ParentCompany id="15262">Vernalis plc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2001-07-26 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="38552">Glutamyl aminopeptidase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17229">INSERM</Company><Country id="FR">France</Country><Drug id="57583">QGC-001</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="178">Hypertension</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-04-13 00:00:00</LatestChange><ParentCompany id="17229">INSERM</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-04-13 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row></Rowset>